Evidence map›Paper›PMID 38580807›Full record

ArticleScientific reports2024

Modified polymeric biomaterials with antimicrobial and immunomodulating properties.

Katarzyna Szałapata, Mateusz Pięt, Martyna Kasela, Marcin Grąz, Justyna Kapral-Piotrowska, Aleksandra Mordzińska-Rak, Elżbieta Samorek, Paulina Pieniądz, Jolanta Polak, Monika Osińska-Jaroszuk and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Katarzyna SzałapataDepartment of Biochemistry and Biotechnology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka, 19, 20-033, Lublin, Poland.
Mateusz PiętDepartment of Virology and Immunology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.
Martyna KaselaDepartment of Pharmaceutical Microbiology, Medical University of Lublin, Chodzki 1, 20-093, Lublin, Poland.
Marcin GrązDepartment of Biochemistry and Biotechnology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka, 19, 20-033, Lublin, Poland.
Justyna Kapral-PiotrowskaDepartment of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.
Aleksandra Mordzińska-RakDepartment of Biochemistry and Biotechnology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka, 19, 20-033, Lublin, Poland.
Elżbieta SamorekDepartment of Virology and Immunology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.
Paulina PieniądzDepartment of Virology and Immunology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.
Jolanta PolakDepartment of Biochemistry and Biotechnology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka, 19, 20-033, Lublin, Poland.
Monika Osińska-JaroszukDepartment of Biochemistry and Biotechnology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka, 19, 20-033, Lublin, Poland.
Roman PaduchDepartment of Virology and Immunology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.
Bożena Pawlikowska-PawlęgaDepartment of Functional Anatomy and Cytobiology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka 19, 20-033, Lublin, Poland.
Anna MalmDepartment of Pharmaceutical Microbiology, Medical University of Lublin, Chodzki 1, 20-093, Lublin, Poland.
Anna Jarosz-WilkołazkaDepartment of Biochemistry and Biotechnology, Institute of Biological Sciences, Maria Curie-Sklodowska University, Akademicka, 19, 20-033, Lublin, Poland. anna.jarosz-wilkolazka@mail.umcs.pl.
Maria Curie-Skłodowska University · PLMedical University of Lublin · PLNational Veterinary Research Institute · PL

Funding

National Science Centre in Poland Opus 2017/25/B/NZ7/01084
6 · The paper itself

Abstract

The modification of the surgical polypropylene mesh and the polytetrafluoroethylene vascular prosthesis with cecropin A (small peptide) and puromycin (aminonucleoside) yielded very stable preparations of modified biomaterials. The main emphasis was placed on analyses of their antimicrobial activity and potential immunomodulatory and non-cytotoxic properties towards the CCD841 CoTr model cell line. Cecropin A did not significantly affect the viability or proliferation of the CCD 841 CoTr cells, regardless of its soluble or immobilized form. In contrast, puromycin did not induce a significant decrease in the cell viability or proliferation in the immobilized form but significantly decreased cell viability and proliferation when administered in the soluble form. The covalent immobilization of these two molecules on the surface of biomaterials resulted in stable preparations that were able to inhibit the multiplication of Staphylococcus aureus and S. epidermidis strains. It was also found that the preparations induced the production of cytokines involved in antibacterial protection mechanisms and stimulated the immune response. The key regulator of this activity may be related to TLR4, a receptor recognizing bacterial LPS. In the present study, these factors were produced not only in the conditions of LPS stimulation but also in the absence of LPS, which indicates that cecropin A- and puromycin-modified biomaterials may upregulate pathways leading to humoral antibacterial immune response.

Indexed as

Anti-Infective AgentsBiocompatible MaterialsAnti-Bacterial AgentsLipopolysaccharidesPolymersPuromycinStaphylococcus epidermidisAnti-Bacterial AgentsAnti-Infective AgentsBiocompatible MaterialsLipopolysaccharidesPolymersPuromycin

Identifiers

PMID38580807
PMCPMC10997598
OpenAlexW4393991827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.